July 14th 2025
Takeda reveals promising phase 3 results for oveporexton, a potential breakthrough treatment for narcolepsy type 1, targeting excessive daytime sleepiness.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
Phase 2 Published Data of Oveporexton Shows Broad Improvements of Narcolepsy Type 1 Symptoms
July 11th 2025The investigational oral orexin receptor 2-selective agonist oveporexton is designed to restore orexin signaling to address the underlying orexin deficiency that is caused by narcolepsy type 1.
LivaNova’s VNS Therapy Maintains Effectiveness in Drug-Resistant Epilepsy in Latest 2-Year Data
July 9th 2025New findings showed that adjunctive VNS therapy led to sustained reductions in generalized tonic-clonic seizure frequency, supporting its long-term efficacy in patients with drug-resistant epilepsy.
NeuroVoices: Kumar Budur, MD, MS, on BP1.15205 as a Next-Gen Therapy for Narcolepsy
The chief medical and scientific officer at Harmony Biosciences discussed the pharmacologic rationale and preclinical development of BP1.15205, a novel orexin receptor 2 agonist for hypersomnolence.
Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH
The professor of neurology at the Miami Miller School of Medicine discussed how the Cognivue Amyloid Risk Measure (CARM) may help predict amyloid presence and informs diagnosis, trial eligibility, and early treatment pathways.
Recognizing Gastrointestinal Symptoms as Early Indicators of Parkinson Disease
Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.